Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Sensory gating deficits have been found in patients with schizophrenia and their unaffected relatives. However, the underlying neurobiological mechanism of this deficit remains unclear. Pre-clinical studies have implicated adenosine in sensory gating deficits in schizophrenia. Therefore, the current study investigated a possible relationship between peripheral adenosine A2A receptor (ADORA2A) and sensory gating indices (P50 measures) in medication-free schizophrenia (n=31) and healthy (n=21) groups. The effects of six-week antipsychotic treatment were examined. At baseline, schizophrenia patients showed impaired sensory gating compared to healthy controls. However, there was no significant difference in ADORA2A gene expression among groups. In addition, ADORA2A expression was not correlated with sensory gating at any time point. Following treatment, we found a significant upregulation of ADORA2A expression. Intriguingly, we observed a significant positive association between ADORA2A upregulation and baseline P50 amplitudes in the schizophrenia group. A main finding of the current pilot study is the upregulation of ADORA2A expression following treatment with antipsychotics. In addition, this upregulation was predicted by baseline P50 amplitude, an observation that awaits replication in an expanded sample.
Mental Health Center, Shantou University Medical College, Taishan North Road, Shantou 515043, Guangdong, PR China.
Jie
J
Zhang
Chadi G
CG
Abdallah
Junqing
J
Wang
Xiaona
X
Wan
Chunlian
C
Liang
Liyun
L
Jiang
Yuzhen
Y
Liu
Haixing
H
Huang
Xiaohong
X
Hong
Qingjun
Q
Huang
Renhua
R
Wu
Chongtao
C
Xu
D000161:Acoustic Stimulation; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000068180:Aripiprazole; D001303:Auditory Cortex / Q000187:drug effects / Q000503:physiopathology; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000494:pharmacology / Q000627:therapeutic use; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000378:metabolism*; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D055139:Sensory Gating / Q000187:drug effects* / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects*
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D043705:Receptor, Adenosine A2A; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000068180:Aripiprazole; D018967:Risperidone; D000077152:Olanzapine